CNEs are oil-in-water emulsions stabilized by cationic lipids like DOTAP, which bind mRNA to resist RNase degradation and boost cellular uptake, offering optimized, stable, cost-effective formulations to speed vaccine, gene therapy, and regenerative medicine development.
It uses advanced engineering and high-throughput screening to accelerate drug discovery, provides end-to-end support, delivers bespoke formulations with strong stability and efficient endosomal escape, and streamlines the path to clinical success.
The core strength of the CNE lies in its meticulously crafted structure. The cationic lipids, once incorporated, electrostatically associate with the anionic mRNA, compacting the payload and creating a dense, stable complex within the emulsion droplet. This dual-protection (oil-in-water stability plus electrostatic shield) ensures the mRNA remains viable in circulation. The final positive surface charge facilitates strong interaction with the target cell membrane, driving successful internalization via endocytosis. Our proprietary formulation strategy then ensures the CNE breaks down efficiently within the endosome, releasing the mRNA into the cytosol before lysosomal fusion occurs.
Our Custom Cationic Nanoemulsion Development Service is highly versatile, supporting a broad spectrum of cutting-edge mRNA applications:
Our phased, rigorous workflow ensures a streamlined and data-driven process, resulting in a high-quality, scalable CNE formulation optimized for your specific therapeutic goal.
Client provides full mRNA sequence, purification data, therapeutic application (e.g., vaccine, protein replacement), and administration route; team defines target product profile (TPP) and formulation strategy.
High-throughput screening of cationic lipid compositions (including proprietary derivatives, DOTAP analogues) and surfactants (e.g., MF59) identifies a lead mixture with maximum mRNA encapsulation efficiency.
Fine-tune process parameters (e.g., sonication protocols, mixing ratios) to control particle size (100-300 nm) and zeta potential; produce pilot CNE batches with high reproducibility and optimal physicochemical properties.
Test lead CNE in relevant cell lines to quantify transfection efficiency, endosomal escape, and payload expression; confirm high transfection and low cytotoxicity.
Develop transferable large-scale manufacturing protocol and regulatory support docs; deliver Formulation Development Report, Scaled-Up Manufacturing Protocol, and In Vitro Efficacy Data Package.
The typical timeframe for this service ranges from 8 to 14 weeks, depending on the complexity of the mRNA sequence and the novelty of the target tissue, with additional time required for extensive in vivo testing if requested.
Discover How We Can Help - Request a Consultation
As an expert seller, I can assure you that our Cationic Nanoemulsion Development Service goes beyond simple formulation—it's a robust partnership in manufacturing readiness. We leverage two decades of expertise to provide a complete, de-risked pathway from research concept to GMP-ready production.
One-stop CNE development ranging from initial research-scale prototyping and formulation screening to pilot-scale production and support for large-scale manufacturing transition.
Focused, efficient nanocarrier formulation (upstream) and purification (downstream) process development tailored specifically for the stability and regulatory needs of nucleic acids.
Access to diverse, scalable non-viral vector manufacturing technologies capable of high industrial throughput.
Implementation of Quality-by-Design (QbD) principles and Process Analytical Technologies (PAT) throughout the CNE formulation process for real-time control and guaranteed reproducibility.
Strict adherence to aseptic verification procedures, Hazard Analysis Critical Control Point (HACCP) methodologies, and the basic principles of Good Manufacturing Practice (GMP) readiness.
Guaranteed physicochemical stability of the CNE formulation, including particle size, zeta potential, and encapsulation efficiency, across various production scales and storage conditions.
Experience the Creative Biolabs Advantage - Get a Quote Today
CNEs often demonstrate superior storage stability due to the intrinsic nature of the emulsion system compared to some LNP formulations. Furthermore, the manufacturing methods for CNEs, such as probe sonication, can be more readily scaled and may offer lower manufacturing costs depending on the complexity of the LNP formulation. We recommend a consultation to compare which proprietary formulation best fits your TPP and cost structure.
The main precaution involves meticulously controlling the surface charge (zeta potential). While a positive charge is essential for cellular uptake, an excessively high positive charge can lead to non-specific binding and systemic toxicity. Our service includes rigorous optimization to find the Goldilocks zone—a charge that maximizes transfection while ensuring high biocompatibility and minimizing adverse immune reactions.
Absolutely. Our hybrid CNE system is inherently robust and highly effective at condensing large payloads. We specifically adjust the cationic lipid-to-mRNA ratio and oil-phase composition to handle the size and complexity of saRNA, guaranteeing intact encapsulation and high-efficacy delivery essential for potent saRNA performance.
Yes, CNEs can be functionalized for targeted delivery. While the base cationic charge drives initial attraction, our service includes options to modify the CNE surface with targeting ligands (e.g., peptides or antibodies) to achieve enhanced specificity for certain cell types, such as dendritic cells for vaccines. Contact us to discuss your specific targeting requirements.
The service solves nucleic acid therapeutics' key hurdle—delivery—by offering one-stop engineering and scaling of hybrid CNE vectors. It maximizes mRNA protection, ensures efficient cytosolic release, meets strict stability and low-toxicity standards, and helps translate mRNA potential into clinical reality.
Contact Our Team for More Information and to Discuss Your Project
| Cat. No | Product Name | Promoter |
|---|---|---|
| CAT#: GTVCR-WQ001MR | IVTScrip™ pT7-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ002MR | IVTScrip™ pT7-VEE-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ003MR | IVTScrip™ pT7-VEE-mRNA-FLuc Vector | T7 |
| CAT#: GTVCR-WQ87MR | IVTScrip™ pT7-VEE-mRNA-Anti-SELP, 42-89-glycoprotein Vector | T7 |
| Cat. No | Product Name | Type |
|---|---|---|
| CAT#: GTTS-WQ001MR) | IVTScrip™ mRNA-EGFP (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| CAT#: GTTS-WK18036MR | IVTScrip™ mRNA-Human AIMP2, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) | Enzyme mRNA |
| (CAT#: GTTS-WQ004MR) | IVTScrip™ mRNA-Fluc (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| (CAT#: GTTS-WQ009MR) | IVTScrip™ mRNA-β gal (Cap 1, 30 nt-poly(A)) | Reporter Gene |
